Skip to main content

Advertisement

Log in

Prokinetics in Diabetic Gastroparesis

  • Neuromuscular Disorders of the Gastrointestinal Tract (A Foxx-Orenstein, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Within the last 50 years, diabetic gastroparesis has become a well recognized complication of type 1 and type 2 diabetes. It is a syndrome characterized by abnormal gastric function, resulting in delayed emptying of the stomach in the absence of any evident mechanical obstruction, predominantly manifested by early satiety, postprandial fullness, nausea, vomiting, and weight loss. The past five years have shown significant advances in its pathophysiology and in new diagnostic tests. Prokinetic medications remain the therapeutic focus for improving clinical symptoms of gastroparesis through enhanced gastric emptying. This article summarizes the present knowledge of prokinetics, with emphasis on medications currently available, as well as drugs under clinical investigation, including some agents in advanced clinical trials that are likely to be used in the treatment of diabetic gastroparesis in the future. These include the ghrelin agonists and newer 5-HT4 agonists devoid of cardiac side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Tonini M, Cipollina L, Poluzzi E, et al. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004;19(4):379–90.

    Article  PubMed  CAS  Google Scholar 

  2. • Reddymasu SC, McCallum RW. Pharmacotherapy of gastroparesis. Expert Opin Pharmacother. 2009;10(3):469–84. A very comprehensive review regarding all available pharmacological modalities utilized to control symptoms of diabetic, idiopathic, and post-surgical gastroparetic patients.

    Article  PubMed  CAS  Google Scholar 

  3. Cellek S, John AK, Thangiah R, et al. 5-HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle. Neurogastroenterol Motil. 2006;18(9):853–61.

    Article  PubMed  CAS  Google Scholar 

  4. Snape Jr WJ, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med. 1982;96(4):444–6.

    PubMed  Google Scholar 

  5. Perkel MS, Moore C, Hersh T, Davidson ED. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study. Dig Dis Sci. 1979;24(9):662–6.

    Article  PubMed  CAS  Google Scholar 

  6. • Lata PF, Pigarelli DL. Chronic metoclopramide therapy for diabetic gastroparesis. Ann Pharmacother. 2003;37(1):122–6. Although studies do not show benefit for the long-term use of metoclopramide, many patients with gastroparesis continue to be on long-term therapy, given the lack of alternative agents.

    Article  PubMed  CAS  Google Scholar 

  7. Schade RR, Dugas MC, Lhotsky DM, Gavaler JS, Van Thiel DH. Effect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis. Dig Dis Sci. 1985;30(1):10–5.

    Article  PubMed  CAS  Google Scholar 

  8. Ricci DA, Saltzman MB, Meyer C, Callachan C, McCallum RW. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol. 1985;7(1):25–32.

    Article  PubMed  CAS  Google Scholar 

  9. Chen JD, Pan J, McCallum RW. Clinical significance of gastric myoelectrical dysrhythmias. Dig Dis. 1995;13(5):275–90.

    Article  PubMed  Google Scholar 

  10. Bradette M, Pare P, Douville P, Morin A. Visceral perception in health and functional dyspepsia. Crossover study of gastric distension with placebo and domperidone. Dig Dis Sci. 1991;36(1):52–8.

    Article  PubMed  CAS  Google Scholar 

  11. McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6(5):463–7.

    Article  PubMed  CAS  Google Scholar 

  12. Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev Endocrinol Metab. 2010;5(5):653–62.

    Article  PubMed  CAS  Google Scholar 

  13. McCallum RW, Valenzuela G, Polepalle S, Spyker D. Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. J Pharmacol Exp Ther. 1991;258(1):136–42.

    PubMed  CAS  Google Scholar 

  14. Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127(5):1592–622.

    Article  PubMed  Google Scholar 

  15. Jolliet P, Nion S, Allain-Veyrac G. Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared with domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood–brain barrier. Pharmacol Res. 2007;56(1):11–7.

    Article  PubMed  CAS  Google Scholar 

  16. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement–a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006;3(3):138–48.

    Article  PubMed  CAS  Google Scholar 

  17. Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med. 1983;98(1):86–95.

    PubMed  CAS  Google Scholar 

  18. Brogden RN, Carmine AA, Heel RC, et al. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic effi cacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs. 1982;24(5):360–400.

    Article  PubMed  CAS  Google Scholar 

  19. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102(9):2036–45.

    Article  PubMed  CAS  Google Scholar 

  20. Heer M, Muller-Duysing W, Benes I, et al. Diabetic gastroparesis: treatment with domperidone–a double-blind, placebo-controlled trial. Digestion. 1983;27(4):214–7.

    Article  PubMed  CAS  Google Scholar 

  21. Horowitz M, Harding PE, Chatterton BE, et al. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci. 1985;30(1):1–9.

    Article  PubMed  CAS  Google Scholar 

  22. Koch KL, Stern RM, Stewart WR, et al. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone treatment. Am J Gastroenterol. 1989;84(9):1069–75.

    PubMed  CAS  Google Scholar 

  23. Patterson D, Abell T, Rothstein R, et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol. 1999;94(5):1230–4.

    PubMed  CAS  Google Scholar 

  24. Soykan I, Sarosiek I, McCallum RW. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol. 1997;92(6):976–80.

    PubMed  CAS  Google Scholar 

  25. McCallum RW. Clinical pharmacology forum: motility agents and the gastrointestinal tract. Am J Med Sci. 1996;312(1):19–26.

    Article  PubMed  CAS  Google Scholar 

  26. Spirt MJ, Chan W, Thieberg M, et al. Neuroleptic malignant syndrome induced by domperidone. Dig Dis Sci. 1992;37(6):946–8.

    Article  PubMed  CAS  Google Scholar 

  27. Sowers JR, Sharp B, McCallum RW. Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18 hydroxycorticosterone secretion in man. J Clin Endocrinol Metab. 1982;54(4):869–71.

    Article  PubMed  CAS  Google Scholar 

  28. • Rossi M, Giorgi G. Domperidone and long QT syndrome. Curr Drug Saf. 2010;5(3):257–62. An important review of data involving potential cardiotoxicity of domperidone with prolongation of QTc intervals. The FDA restrictions, lack of approval, and limited list of available prokinetics makes this paper of special interest in a field of gastroparesis.

    Article  PubMed  CAS  Google Scholar 

  29. Basque JR, Noritake M, Mizogami H, et al. Effi cacy of itopride hydrochloride on gastric emptying in patients with diabetic gastroparesis. Gastroenterology. 2005;128:A156 (abstract).

    Google Scholar 

  30. Stevens JE, Russo A, Maddox AF, et al. Effect of itopride on gastric emptying in longstanding diabetes mellitus. Neurogastroenterol Motil. 2008;20(5):456–63.

    Article  PubMed  CAS  Google Scholar 

  31. Catnach SM, Fairclough PD. Erythromycin and the gut. Gut. 1992;33(3):397–401.

    Article  PubMed  CAS  Google Scholar 

  32. Parkman HP, Pagano AP, Vozzelli MA, et al. Gastrokinetic effects of erythromycin: myogenic and neurogenic mechanisms of action in rabbit stomach. Am J Physiol. 1995;269(3 Pt 1):G418–26.

    PubMed  CAS  Google Scholar 

  33. Peeters TL, Depoortere I. Motilin receptor: a model for development of prokinetics. Dig Dis Sci. 1994;39(12 Suppl):76S–8S.

    Article  PubMed  CAS  Google Scholar 

  34. Kendall BJ, Chakravarti A, Kendall E, et al. The effect of intravenous erythromycin on solid meal gastric emptying in patients with chronic symptomatic post-vagotomy-antrectomy gastroparesis. Aliment Pharmacol Ther. 1997;11(2):381–5.

    Article  PubMed  CAS  Google Scholar 

  35. Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol. 2003;98(2):259–63.

    PubMed  CAS  Google Scholar 

  36. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol. 1993;88(2):203–7.

    PubMed  CAS  Google Scholar 

  37. Sutera L, Dominguez LJ, Belvedere M, et al. Azithromycin in an older woman with diabetic gastroparesis. Am J Ther. 2008;15(1):85–8.

    Article  PubMed  Google Scholar 

  38. Bortolotti M, Gentilini L, Morselli C, et al. Gastroparesis refractory to prokinetics: neuromuscular unresponsiveness or faulty bioavailability of the drug? Dig Dis Sci. 2005;50(5):882–4.

    Article  PubMed  Google Scholar 

  39. Bortolotti M, Mari C, Brunelli F, et al. Effect of intravenous clarithromycin on interdigestive gastroduodenal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. Dig Dis Sci. 1999;44(12):2439–42.

    Article  PubMed  CAS  Google Scholar 

  40. Bortolotti M, Brunelli F, Sarti P, et al. Effects of oral clarithromycin and amoxicillin on interdigestive gastrointestinal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. Aliment Pharmacol Ther. 1998;12(10):1021–5.

    Article  PubMed  CAS  Google Scholar 

  41. Guo D, Cai Y, Chai D, Liang B, Bai N, Wang R. The cardiotoxicity of macrolides: a systematic review. Pharmazie. 2010;65(9):631–40.

    PubMed  CAS  Google Scholar 

  42. McCallum RW, Cynshi O. Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi-center, placebo-controlled trial. Aliment Pharmacol Ther. 2007;26(1):107–16.

    Article  PubMed  CAS  Google Scholar 

  43. McCallum RW, Cynshi O. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study. Aliment Pharmacol Ther. 2007;26(8):1121–30.

    Article  PubMed  CAS  Google Scholar 

  44. Fraser RJ, Horowitz M, Maddox AF, et al. Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis–effects of cisapride. Gut. 1994;35(2):172–8.

    Article  PubMed  CAS  Google Scholar 

  45. Fraser R, et al. Dual effects of cisapride on gastric emptying and antropyloroduodenal motility. Am J Physiol. 1993;264(2 Pt 1):G195–201.

    PubMed  CAS  Google Scholar 

  46. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA. 2000;284(23):3036–9.

    Article  PubMed  CAS  Google Scholar 

  47. Degen L, et al. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil. 2005;17(6):821–6.

    Article  PubMed  CAS  Google Scholar 

  48. Degen L, Petrig C, Studer D, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther. 2001;15(11):1745–51.

    Article  PubMed  CAS  Google Scholar 

  49. Asakawa H, Hayashi I, Fukui T, et al. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy. Diabetes Res Clin Pract. 2003;61(3):175–82.

    Article  PubMed  CAS  Google Scholar 

  50. Potet F, Bouyssou T, Escande D, et al. Gastrointestinal prokinetic drugs have different affi nity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther. 2001;299(3):1007–12.

    PubMed  CAS  Google Scholar 

  51. Mackie AD, Ferrington C, Cowan S, et al. The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis. Aliment Pharmacol Ther. 1991;5(2):135–42.

    Article  PubMed  CAS  Google Scholar 

  52. Manabe N, Wong BS, Camilleri M. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs. 2010;19:765–75.

    Article  PubMed  CAS  Google Scholar 

  53. Bortolotti M, Cucchiara S, Sarti P, et al. Comparison between the effects of neostigmine and ranitidine on interdigestive gastroduodenal motility of patients with gastroparesis. Digestion. 1995;56(2):96–9.

    Article  PubMed  CAS  Google Scholar 

  54. Lucey MA, Patil V, Girling K, et al. Does neostigmine increase gastric emptying in the critically ill? – results of a pilot study. Crit Care Resusc. 2003;5(1):14–9.

    PubMed  CAS  Google Scholar 

  55. Lehmann A. Z-338. Zeria/Yamanouchi. Curr Opin Investig Drugs. 2004;5(7):760–5.

    PubMed  CAS  Google Scholar 

  56. Seto K, Sasaki T, Katsunuma K, et al. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil. 2008;20(9):1051–9.

    Article  PubMed  CAS  Google Scholar 

  57. Kei M, Michio H, Daisuke S, et al. Dose-Dependent Therapeutic Effi cacy of Acotiamide (Z-338) in Patients with Functional Dyspepsia: 100 Mg tid Is An Optimal Dosage. DDW 2008. Abstract 1027.

  58. McCallum RW, Fink SM, Lerner E, et al. Effects of metoclopramide and bethanechol on delayed gastric emptying present in gastroesophageal refl ux patients. Gastroenterology. 1983;84(6):1573–7.

    PubMed  CAS  Google Scholar 

  59. Parkman HP, Pagano AP, Ryan JP, Pagano AP, Ryan JP. Ranitidine and nizatidine stimulate antral smooth muscle contractility via excitatory cholinergic mechanisms. Dig Dis Sci. 1998;43(3):497–505.

    Article  PubMed  CAS  Google Scholar 

  60. Koskenpato J, Punkkinen JM, Kairemo K, et al. Nizatidine and gastric emptying in functional dyspepsia. Dig Dis Sci. 2008;53(2):352–7.

    Article  PubMed  CAS  Google Scholar 

  61. • McCallum RW, Zarling EJ, Goetsch AC, Griffin C, Sarosiek I, Hejazi RA, et al. Multicenter, double-blind, placebo-controlled crossover study to assess the acute prokinetic efficacy of nizatidine-controlled release (150 and 300 mg) in patients with gastroesophageal reflux disease. Am J Med Sci. 2010;340(4):259–63. A very interesting study designed to investigate the prokinetic activities of a well-known acid-reducing agent. It provides an especially important adjuvant therapeutic option in patients who aside from gastroparesis, suffer from GERD symptoms.

    Article  PubMed  Google Scholar 

  62. Dornonville de la Cour C, Lindstrom E, Norlen P, et al. Ghrelin stimulates gastric emptying but is without effect on acid secretion and gastric endocrine cells. Regul Pept. 2004;120(1–3):23–32.

    Article  PubMed  CAS  Google Scholar 

  63. Trudel L, Tomasetto C, Rio MC, et al. Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. Am J Physiol Gastrointest Liver Physiol. 2002;282(6):G948–52.

    PubMed  CAS  Google Scholar 

  64. Tack J, Depoortere I, Bisschops R, et al. Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut. 2006;55(3):327–33.

    Article  PubMed  CAS  Google Scholar 

  65. Levin F, Edholm T, Schmidt PT, et al. Ghrelin stimulates gastric emptying and hunger in normal-weight humans. J Clin Endocrinol Metab. 2006;91(9):3296–302.

    Article  PubMed  CAS  Google Scholar 

  66. Murray CD, Martin NM, Patterson M, et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut. 2005;54(12):1693–8.

    Article  PubMed  CAS  Google Scholar 

  67. Tack J, Depoortere I, Bisschops R, et al. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther. 2005;22(9):847–53.

    Article  PubMed  CAS  Google Scholar 

  68. • Ejskjaer N, Dimcevski G, Wo J, Hellström PM, Gormsen LC, Sarosiek I, et al. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol Motil. 2010;22(10):1069-e281. This article, we believe, is the first published data reporting the clinical efficacy of IV ghrelin agonist studied in diabetic populations of gastroparetic patients.

    Article  PubMed  Google Scholar 

  69. Wo JM, Ejskjaer N, Hellström PM, Malik RA, Pezzullo JC, Shaughnessy L, et al. Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting - randomised clinical study subset data. Aliment Pharmacol Ther. 2011;33(6):679–88.

    Article  PubMed  CAS  Google Scholar 

  70. Grider JR, Makhlouf GM. Distinct receptors for cholecystokinin and gastrin on muscle cells of stomach and gallbladder. Am J Physiol. 1990;259(2 Pt 1):G184–90.

    PubMed  CAS  Google Scholar 

  71. Schwizer W, Borovicka J, Kunz P, et al. Role of cholecystokinin in the regulation of liquid gastric emptying and gastric motility in humans: studies with the CCK antagonist loxiglumide. Gut. 1997;41(4):500–4.

    Article  PubMed  CAS  Google Scholar 

  72. Scarpignato C, Kisfalvi I, D’Amato M, et al. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther. 1996;10(3):411–9.

    Article  PubMed  CAS  Google Scholar 

  73. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004;16 Suppl 2:17–28.

    Article  PubMed  Google Scholar 

  74. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332–43.

    Article  PubMed  CAS  Google Scholar 

  75. Huilgol V, Evans J, Hellman RS, et al. Acute effect of clonidine on gastric emptying in patients with diabetic gastropathy and controls. Aliment Pharmacol Ther. 2002;16(5):945–50.

    Article  PubMed  CAS  Google Scholar 

  76. Boeckxstaens GE. Reflux inhibitors: a new approach for GERD? Curr Opin Pharmacol 2008.

  77. Omari TI, Benninga MA, Sansom L, et al. Effect of baclofen on esophagogastric motility and gastroesophageal refl ux in children with gastroesophageal refl ux disease: a randomized controlled trial. J Pediatr. 2006;149(4):468–74.

    Article  PubMed  CAS  Google Scholar 

  78. Izzo AA. The cannabinoid CB(2) receptor: a good friend in the gut. Neurogastroenterol Motil. 2007;19(9):704–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Irene Sarosiek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hejazi, R.A., McCallum, R.W. & Sarosiek, I. Prokinetics in Diabetic Gastroparesis. Curr Gastroenterol Rep 14, 297–305 (2012). https://doi.org/10.1007/s11894-012-0275-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-012-0275-3

Keywords

Navigation